<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34983286</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1933-6969</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Channels (Austin, Tex.)</Title>
          <ISOAbbreviation>Channels (Austin)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Small molecule targeting NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in chronic constriction injury (CCI) rats.</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>8</EndPage>
          <MedlinePgn>1-8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/19336950.2021.2023383</ELocationID>
        <Abstract>
          <AbstractText>The voltage-gated sodium channel isoform NaV1.7 is a critical player in the transmission of nociceptive information. This channel has been heavily implicated in human genetic pain disorders and is a validated pain target. However, targeting this channel directly has failed, and an indirect approach - disruption of interactions with accessory protein partners - has emerged as a viable alternative strategy. We recently reported that a small-molecule inhibitor of CRMP2 SUMOylation, compound <b>194</b>, selectively reduces NaV1.7 currents in DRG neurons across species from mouse to human. This compound also reversed mechanical allodynia in a spared nerve injury and chemotherapy-induced model of neuropathic pain. Here, we show that oral administration of <b>194</b> reverses mechanical allodynia in a chronic constriction injury (CCI) model of neuropathic pain. Furthermore, we show that orally administered <b>194</b> reverses the increased latency to cross an aversive barrier in a mechanical conflict-avoidance task following CCI. These two findings, in the context of our previous report, support the conclusion that <b>194</b> is a robust inhibitor of NaV1.7 function with the ultimate effect of profoundly ameliorating mechanical allodynia associated with nerve injury. The fact that this was observed using both traditional, evoked measures of pain behavior as well as the more recently developed operator-independent mechanical conflict-avoidance assay increases confidence in the efficacy of <b>194</b>-induced anti-nociception.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jiahe</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratories of Neuroimmunology, Department of Symptom Research, The University of Texas, Houston, Texas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stratton</LastName>
            <ForeName>Harrison J</ForeName>
            <Initials>HJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, Arizona, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lorca</LastName>
            <ForeName>Sabina A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratories of Neuroimmunology, Department of Symptom Research, The University of Texas, Houston, Texas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grace</LastName>
            <ForeName>Peter M</ForeName>
            <Initials>PM</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratories of Neuroimmunology, Department of Symptom Research, The University of Texas, Houston, Texas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khanna</LastName>
            <ForeName>Rajesh</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0002-9066-2969</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, Arizona, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Comprehensive Pain and Addiction Center, The University of Arizona, Tucson, Arizona, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 DA042852</GrantID>
            <Acronym>DA</Acronym>
            <Agency>NIDA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS098772</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS120663</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Channels (Austin)</MedlineTA>
        <NlmUniqueID>101321614</NlmUniqueID>
        <ISSNLinking>1933-6950</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D062556">NAV1.7 Voltage-Gated Sodium Channel</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003250" MajorTopicYN="N">Constriction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005727" MajorTopicYN="N">Ganglia, Spinal</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006930" MajorTopicYN="N">Hyperalgesia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062556" MajorTopicYN="Y">NAV1.7 Voltage-Gated Sodium Channel</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009437" MajorTopicYN="Y">Neuralgia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">CRMP2</Keyword>
        <Keyword MajorTopicYN="Y">Chronic pain</Keyword>
        <Keyword MajorTopicYN="Y">NaV1.7</Keyword>
        <Keyword MajorTopicYN="Y">SUMOylation</Keyword>
        <Keyword MajorTopicYN="Y">Ubc9</Keyword>
        <Keyword MajorTopicYN="Y">nociceptor</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>5</Day>
          <Hour>5</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34983286</ArticleId>
        <ArticleId IdType="pmc">PMC8741281</ArticleId>
        <ArticleId IdType="doi">10.1080/19336950.2021.2023383</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Todd AJ.
Neuronal circuitry for pain processing in the dorsal horn. Nat Rev Neurosci. 2010;11(12):823–836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3277941</ArticleId>
            <ArticleId IdType="pubmed">21068766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sherrington CS. Qualitative difference of spinal reflex corresponding with qualitative difference of cutaneous stimulus. J Physiol. 1903;30:39–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1540657</ArticleId>
            <ArticleId IdType="pubmed">16992687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basbaum AI, Bautista DM, Scherrer G, et al. Cellular and molecular mechanisms of pain. Cell. 2009;139:267–284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2852643</ArticleId>
            <ArticleId IdType="pubmed">19837031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willis WD. Sensory mechanisms of the spinal cord volume 1 primary afferent neurons and the spinal dorsal horn. Boston (MA): Boston (MA): Springer US: Imprint: Springer; 2004.</Citation>
        </Reference>
        <Reference>
          <Citation>Black JA, Frezel N, Dib-Hajj SD, et al. Expression of Nav1.7 in DRG neurons extends from peripheral terminals in the skin to central preterminal branches and terminals in the dorsal horn. Mol Pain. 2012;8:82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3517774</ArticleId>
            <ArticleId IdType="pubmed">23134641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cummins TR, Howe JR, Waxman SG. Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. J Neurosci. 1998;18:9607–9619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6793269</ArticleId>
            <ArticleId IdType="pubmed">9822722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herzog RI, Cummins TR, Ghassemi F, et al. Distinct repriming and closed-state inactivation kinetics of Nav1.6 and Nav1.7 sodium channels in mouse spinal sensory neurons. J Physiol. 2003;551:741–750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2343279</ArticleId>
            <ArticleId IdType="pubmed">12843211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drenth JP, Waxman SG. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest. 2007;117:3603–3609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2096434</ArticleId>
            <ArticleId IdType="pubmed">18060017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, Wang Y, Li S, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet. 2004;41:171–174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1735695</ArticleId>
            <ArticleId IdType="pubmed">14985375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fertleman CR, Baker MD, Parker KA, et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron. 2006;52(5):767–774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17145499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox JJ, Reimann F, Nicholas AK, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444:894–898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7212082</ArticleId>
            <ArticleId IdType="pubmed">17167479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexandrou AJ, Brown AR, Chapman ML, et al. SubtypeSelective small molecule inhibitors reveal a fundamental role for Nav1.7 in nociceptor electrogenesis, axonal conduction and presynaptic release. PLoS One. 2016;11:e0152405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4822888</ArticleId>
            <ArticleId IdType="pubmed">27050761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCormack K, Santos S, Chapman ML, et al. Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels. Proc Natl Acad Sci U S A. 2013;110:E2724–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3718154</ArticleId>
            <ArticleId IdType="pubmed">23818614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siebenga P, van Amerongen G, Hay JL, et al. Lack of detection of the analgesic properties of PF-05089771, a selective Na(v) 1.7 inhibitor, using a battery of pain models in healthy subjects. Clin Transl Sci. 2020;13:318–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7070789</ArticleId>
            <ArticleId IdType="pubmed">31642607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eagles DA, Chow CY, King GF. Fifteen years of NaV1.7 channels as an analgesic target: why has excellent in vitro pharmacology not translated into in vivo analgesic efficacy?. Br J Pharmacol. 2020 Nov 18. doi:10.1111/bph.15327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bph.15327</ArticleId>
            <ArticleId IdType="pubmed">33206998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodwin G, McMahon SB. The physiological function of different voltage-gated sodium channels in pain. Nat Rev Neurosci. 2021;22:263–274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33782571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dustrude ET, Wilson SM, Ju W, et al. CRMP2 protein SUMOylation modulates NaV1.7 channel trafficking. J Biol Chem. 2013;288:24316–24331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3750134</ArticleId>
            <ArticleId IdType="pubmed">23836888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dustrude ET, Moutal A, Yang X, et al. Hierarchical CRMP2 posttranslational modifications control NaV1.7 function. Proc Natl Acad Sci U S A. 2016;113:E8443–E52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5206544</ArticleId>
            <ArticleId IdType="pubmed">27940916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dustrude ET, Perez-Miller S, Francois-Moutal L, et al. A single structurally conserved SUMOylation site in CRMP2 controls NaV1.7 function. Channels (Austin). 2017;11:316–328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5555265</ArticleId>
            <ArticleId IdType="pubmed">28277940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Francois-Moutal L, Dustrude ET, Wang Y, et al. Inhibition of the Ubc9 E2 SUMO-conjugating enzyme-CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain. Pain. 2018;159:2115–2127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6150792</ArticleId>
            <ArticleId IdType="pubmed">29847471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chew LA, Khanna R. CRMP2 and voltage-gated ion channels: potential roles in neuropathic pain. Neuronal Signaling. 2018;2:NS20170220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6197809</ArticleId>
            <ArticleId IdType="pubmed">30364788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chew LA, Bellampalli SS, Dustrude ET, et al. Mining the Nav1.7 interactome: opportunities for chronic pain therapeutics. Biochem Pharmacol. 2019;163:9–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6470000</ArticleId>
            <ArticleId IdType="pubmed">30699328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stratton H, Boinon L, Moutal A, et al. Coordinating synaptic signaling with CRMP2. Int J Biochem Cell Biol. 2020;124:105759.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32437854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moutal A, Ji Y, Bellampalli SS, et al. Differential expression of Cdk5 phosphorylated CRMP2 following a spared nerve injury. Mol Brain. 2020;13:97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7310452</ArticleId>
            <ArticleId IdType="pubmed">32571373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moutal A, Cai S, Yu J, et al. Studies on CRMP2 SUMOylation-deficient transgenic mice identify sex-specific Nav1.7 regulation in the pathogenesis of chronic neuropathic pain. Pain. 2020;161:2629–2651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7572581</ArticleId>
            <ArticleId IdType="pubmed">32569093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomez K, Ran D, Madura CL, et al. Non-SUMOylated CRMP2 decreases Na(V)1.7 currents via the endocytic proteins Numb, Nedd4-2 and Eps15. Mol Brain. 2021;14:20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7819318</ArticleId>
            <ArticleId IdType="pubmed">33478555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai S, Moutal A, Yu J, et al. Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents. Sci Transl Med. 2021;13:eabh1314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34757807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brittain JM, Chen L, Wilson SM, et al. Neuroprotection against traumatic brain injury by a peptide derived from the collapsin response mediator protein 2 (CRMP2). J Biol Chem. 2011;286:37778–37792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3199520</ArticleId>
            <ArticleId IdType="pubmed">21832084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brittain JM, Pan R, You H, et al. Disruption of NMDAR-CRMP-2 signaling protects against focal cerebral ischemic damage in the rat middle cerebral artery occlusion model. Channels (Austin). 2012;6:52–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367672</ArticleId>
            <ArticleId IdType="pubmed">22373559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brittain MK, Brustovetsky T, Sheets PL, et al. Delayed calcium dysregulation in neurons requires both the NMDA receptor and the reverse Na+/Ca2+ exchanger. Neurobiol Dis. 2012;46:109–117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3299854</ArticleId>
            <ArticleId IdType="pubmed">22249110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brustovetsky T, Pellman JJ, Yang XF, et al. Collapsin response mediator protein 2 (CRMP2) interacts with N-methyl-D-aspartate (NMDA) receptor and Na+/Ca2+ exchanger and regulates their functional activity. J Biol Chem. 2014;289:7470–7482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3953261</ArticleId>
            <ArticleId IdType="pubmed">24474686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji Y, Hu Y, Ren J, et al. CRMP2-derived peptide ST2-104 (R9-CBD3) protects SH-SY5Y neuroblastoma cells against Abeta 25-35-induced neurotoxicity by inhibiting the pCRMP2/NMDAR2B signaling pathway. Chem Biol Interact. 2019;305:28–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30871964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu H, Shin SM, Xiang H, et al. AAV-encoded CaV2.2 peptide aptamer CBD3A6K for primary sensory neuron-targeted treatment of established neuropathic pain. Gene Ther. 2019;26:308–323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6707887</ArticleId>
            <ArticleId IdType="pubmed">31118475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buchta WC, Moutal A, Hines B, et al. Dynamic CRMP2 regulation of CaV2.2 in the prefrontal cortex contributes to the reinstatement of cocaine seeking. Mol Neurobiol. 2019;57:346–357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6980501</ArticleId>
            <ArticleId IdType="pubmed">31359322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J, Moutal A, Dorame A, et al. Phosphorylated CRMP2 regulates spinal nociceptive neurotransmission. Mol Neurobiol. 2019;56:5241–5255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6581648</ArticleId>
            <ArticleId IdType="pubmed">30565051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moutal A, Sun L, Yang X, et al. CRMP2-neurofibromin interface drives NF1-related pain. Neuroscience. 2018;381:79–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5963520</ArticleId>
            <ArticleId IdType="pubmed">29655575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moutal A, Wang Y, Yang X, et al. Dissecting the role of the CRMP2-neurofibromin complex on pain behaviors. Pain. 2017;158:2203–2221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6359908</ArticleId>
            <ArticleId IdType="pubmed">28767512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moutal A, Yang X, Li W, et al. CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide. Pain. 2017;158:2301–2319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6362827</ArticleId>
            <ArticleId IdType="pubmed">28809766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moutal A, Francois-Moutal L, Perez-Miller S, et al. (S)Lacosamide binding to collapsin response mediator protein 2 (CRMP2) regulates CaV2.2 activity by subverting its phosphorylation by Cdk5. Mol Neurobiol. 2016;53:1959–1976.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25846820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moutal A, Chew LA, Yang X, et al. (S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology. Pain. 2016;157:1448–1463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4936788</ArticleId>
            <ArticleId IdType="pubmed">26967696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Francois-Moutal L, Wang Y, Moutal A, et al. A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors. Pain. 2015;156:1247–1264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5766324</ArticleId>
            <ArticleId IdType="pubmed">25782368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ju W, Li Q, Wilson SM, et al. SUMOylation alters CRMP2 regulation of calcium influx in sensory neurons. Channels (Austin). 2013;7:153–159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3710342</ArticleId>
            <ArticleId IdType="pubmed">23510938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piekarz AD, Due MR, Khanna M, et al. CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy. Mol Pain. 2012;8:54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3502107</ArticleId>
            <ArticleId IdType="pubmed">22828369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson SM, Schmutzler BS, Brittain JM, et al. Inhibition of transmitter release and attenuation of AIDS therapy-induced and tibial nerve injury-related painful peripheral neuropathy by novel synthetic Ca2+ channel peptides. J Biol Chem. 2012;287:35065–35077.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3471755</ArticleId>
            <ArticleId IdType="pubmed">22891239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ripsch MS, Ballard CJ, Khanna M, et al. A peptide uncoupling CRMP-2 from the presynaptic Ca2+ channel complex demonstrate efficacy in animal models of migraine and AIDS therapy-induced neuropathy. Transl Neurosci. 2012;3:1–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3365854</ArticleId>
            <ArticleId IdType="pubmed">22662308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brittain JM, Wang Y, Eruvwetere O, et al. Cdk5-mediated phosphorylation of CRMP-2 enhances its interaction with CaV2.2. FEBS Lett. 2012;586:3813–3818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23022559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ju W, Li Q, Allette YM, et al. Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginineconjugated CRMP2 peptide. J Neurochem. 2012;124:869–879.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3584205</ArticleId>
            <ArticleId IdType="pubmed">23106100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brittain JM, Duarte DB, Wilson SM, et al. Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca(2)(+) channel complex. Nat Med. 2011;17:822–829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3219927</ArticleId>
            <ArticleId IdType="pubmed">21642979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moutal A, Dustrude ET, Largent-Milnes TM, et al. Blocking CRMP2 SUMOylation reverses neuropathic pain. Mol Psychiatry. 2018;23:211921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5700854</ArticleId>
            <ArticleId IdType="pubmed">28533518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Macedo FHP, Aires RD, Fonseca EG, et al. TNF-α mediated upregulation of Na(V)1.7 currents in rat dorsal root ganglion neurons is independent of CRMP2 SUMOylation. Mol Brain. 2019;12:117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6937926</ArticleId>
            <ArticleId IdType="pubmed">31888677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Francois-Moutal L, Scott DD, Perez-Miller S, et al. Chemical shift perturbation mapping of the Ubc9-CRMP2 interface identifies a pocket in CRMP2 amenable for allosteric modulation of Nav1.7 channels. Channels (Austin). 2018;12:219–227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6104687</ArticleId>
            <ArticleId IdType="pubmed">30081699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uchida Y, Ohshima T, Yamashita N, et al. Semaphorin3A signaling mediated by Fyn-dependent tyrosine phosphorylation of collapsin response mediator protein 2 at tyrosine 32. J Biol Chem. 2009;284:27393–27401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2785668</ArticleId>
            <ArticleId IdType="pubmed">19652227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varrin-Doyer M, Vincent P, Cavagna S, et al. Phosphorylation of collapsin response mediator protein 2 on Tyr-479 regulates CXCL12induced T lymphocyte migration. J Biol Chem. 2009;284:13265–13276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2676058</ArticleId>
            <ArticleId IdType="pubmed">19276087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morinaka A, Yamada M, Itofusa R, et al. Thioredoxin mediates oxidation-dependent phosphorylation of CRMP2 and growth cone collapse. Sci Signal. 2011;4:ra26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21521879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khanna R, Wilson SM, Brittain JM, et al. Opening Pandora’s jar: a primer on the putative roles of CRMP2 in a panoply of neurodegenerative, sensory and motor neuron, and central disorders. Future Neurol. 2012;7:749–771.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3539824</ArticleId>
            <ArticleId IdType="pubmed">23308041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sadler KE, Mogil JS, Stucky CL. Innovations and advances in modelling and measuring pain in animals. Nat Rev Neurosci. 2021. DOI:10.1038/s41583-021-00536-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41583-021-00536-7</ArticleId>
            <ArticleId IdType="pubmed">34837072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berge O-G. Predictive validity of behavioural animal models for chronic pain. Br J Pharmacol. 2011;164:1195–1206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3229757</ArticleId>
            <ArticleId IdType="pubmed">21371010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33:87–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2837713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Odem MA, Lacagnina MJ, Katzen SL, et al. Sham surgeries for central and peripheral neural injuries persistently enhance pain-avoidance behavior as revealed by an operant conflict test. Pain. 2019;160:2440–2455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6800634</ArticleId>
            <ArticleId IdType="pubmed">31323014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kingwell K. Navigating a new path to Nav1.7 for pain. Nat Rev Drug Discov. 2021. DOI:10.1038/d41573-021-00197-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/d41573-021-00197-2</ArticleId>
            <ArticleId IdType="pubmed">34824392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grace PM, Strand KA, Galer EL, et al. Morphine paradoxically prolongs neuropathic pain in rats by amplifying spinal NLRP3 inflammasome activation. Proc Natl Acad Sci U S A. 2016;113:E3441–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4914184</ArticleId>
            <ArticleId IdType="pubmed">27247388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grace PM, Wang X, Strand KA, et al. DREADDed microglia in pain: implications for spinal inflammatory signaling in male rats. Exp Neurol. 2018;304:125–131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5916033</ArticleId>
            <ArticleId IdType="pubmed">29530713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaplan SR, Bach FW, Pogrel JW, et al. Quantitative assessment of tactile allodynia in the rat paw. JNeurosciMethods. 1994;53:55–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7990513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Treutwein B, Strasburger H. Fitting the psychometric function. Percept Psychophys. 1999;61:87–106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10070202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harvey LO Jr. Efficient estimation of sensory thresholds with ML-PEST. Spat Vis. 1997;11:121–128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9304762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Ma J, Lacagnina MJ, et al. Oral dimethyl fumarate reduces peripheral neuropathic pain in rodents via NFE2L2 antioxidant signaling. Anesthesiology. 2020;132:343–356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6993879</ArticleId>
            <ArticleId IdType="pubmed">31939850</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
